Avalyn Pharma Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lyn Baranowski
- Full Time Employees
- 50
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 105 W First St. Boston Boston MA United States of America 02127
- IPO Date
- Apr 30, 2026
- CIK
- 0001540171
- Website
- avalynpharma.com
- Similar Companies
- Business
- Avalyn Pharma Inc. engages in the development of inhaled therapies for rare and progressive lung diseases, with a focus on targeted treatments for interstitial lung diseases including pulmonary fibrosis. The company advances its portfolio of inhaled formulations designed to improve lung-directed delivery and reduce systemic exposure, aiming to address unmet medical needs in IPF and related conditions. Headquartered in Cambridge, Massachusetts, Avalyn Pharma operates primarily in the United States with clinical-stage programs pursued through global partnerships and multicenter trials. Main products and services - Inhaled antifibrotic therapeutics: AP01, an inhaled pirfenidone formulation optimized for distal lung deposition to treat progressive pulmonary fibrosis; and AP02, an inhaled nintedanib formulation intended for similar indications; both designed to deliver targeted therapy to the lungs while minimizing systemic exposure. These candidates are developed to treat idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. - Clinical development services and partnerships: design and management of global Phase 2/3 clinical trials for inhaled therapies in interstitial lung disease, including trial execution, regulatory support, and data generation to support potential regulatory submissions. - Pipeline acceleration and regulatory strategy: ongoing development programs, milestones, and coordination of non-dilutive and equity financing activities to advance lead assets toward mid-to-late-stage evaluation and potential commercialization options. Latest major company changes - Strategic financing and IPO activity: Avalyn files and completes a public offering to raise capital for continued development of its inhaled therapies, with shares trading on a major U.S. exchange under a defined ticker symbol; proceeds are allocated to advancing AP01 and AP02 through mid-to-late-stage development, manufacturing scale-up, and regulatory activities. The IPO confirms a broad equity financing strategy to support expansion of the company’s clinical and operational footprint. - Expanded clinical program activity: initiation or expansion of global Phase 2b/Phase 2 studies for AP01 and AP02 in pulmonary fibrosis and related interstitial lung diseases, with trial sites and enrollment across multiple regions to generate robust efficacy and safety data. - Operational and governance development: enhancement of corporate structure and strategic partnerships to support cross-border clinical trial operations, manufacturing collaborations, and potential future licensing or commercialization arrangements. - Product pipeline progression: continued advancement of inhaled therapies for interstitial lung disease, including optimization of formulation, delivery devices, and patient-selected administration routes to improve adherence and outcomes. Additional context - Industry and segments: biopharmaceuticals focused on respiratory diseases, with emphasis on inhaled therapies for interstitial lung disease and pulmonary fibrosis; research and development activities span preclinical to mid-stage clinical programs, with potential future commercialization opportunities. - Target markets: patients with idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases; healthcare systems and specialty therapeutic areas seeking lung-targeted anti-fibrotic options. - Geographic operations: United States with clinical trial activity that may extend to international sites for global studies; potential partnerships with global manufacturers and contract research organizations to support trial execution. - Founding year and headquarters: founded in the 2020s; headquartered in Cambridge, Massachusetts. - Subsidiaries and parent relationships: operates as an independent company advancing its own inhaled therapy programs; may engage in strategic collaborations and licensing arrangements with partner organizations.
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Avalyn to Participate in the Jefferies Global Healthcare Conference
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
First Look: Berkshire (BRK.B) cash record, GameStop (GME) $56B eBay bid
U.S. IPO Weekly Recap: Biotech, Early-Stage Mining, And Bill Ackman Close Out The April IPO Market
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Avalyn Announces Pricing of Upsized Initial Public Offering
U.S. IPO Weekly Recap: Nuclear Tech, Critical Materials, And More In A 4 IPO Week
U.S. IPO Weekly Recap: Pipeline Swells With Sizable IPO Filings As Metals Royalty Direct Lists